Quick Dispatch:
Your hengrui glp-1 China Hengrui Medicine has registered a Phase III, multicenter, randomized, double-blind clinical trial of the GLP-1R/GIPR dual agonist HRS9531 for the treatment of obesity (NCT06396429; HRS9531-301) orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your hengrui glp-1 China Hengrui Medicine has registered a Phase III, multicenter, randomized, double-blind clinical trial of the GLP-1R/GIPR dual agonist HRS9531 for the treatment of obesity (NCT06396429; HRS9531-301) ships.
Need Help?
Questions about hengrui glp-1 China Hengrui Medicine has registered a Phase III, multicenter, randomized, double-blind clinical trial of the GLP-1R/GIPR dual agonist HRS9531 for the treatment of obesity (NCT06396429; HRS9531-301), sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for hengrui glp-1 China Hengrui Medicine has registered a Phase III, multicenter, randomized, double-blind clinical trial of the GLP-1R/GIPR dual agonist HRS9531 for the treatment of obesity (NCT06396429; HRS9531-301) in your area.
The Race Is On: Winning Smart in the Intensifying GLP-1 Market in China
25.28
Hengrui, Kailera say dual-acting obesity shot succeeds in China study
22.53
Jiangsu Hengrui Competitive Landscape Analysis 2026
21.97
Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions
25.78
Hengrui, Kailera tout positive results for dual-acting obesity pill
28.00
Jiangsu Hengrui Pharmaceuticals Out-Licenses GLP-1 Portfolio // Cooley // Global Law Firm
22.58
⚡️ 19.2 Percent
24.94
